{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093356","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.044765+00:00","generated_at":"2026-05-31T11:01:32.559702+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aptevo posts Q2 net loss $5.9M, cash $8.1M; APVO436 Phase 1b/2 trial to begin","bullets":["Net loss of $5.9M ($1.67/sh) vs $7.9M ($53.95/sh) in Q2 2023; R&D spend down 33% to $3.6M.","Cash $8.1M at June 30; proforma $10.4M including $2.75M July direct offering, extending runway into 2025.","APVO436 Phase 1b/2 dose optimization trial for AML expected to start in Q3 2024; prior expansion showed 91% clinical benefit rate.","ALG.APV-527 solid-tumor trial >90% enrolled; data showed durable stable disease in two heavily pretreated breast cancer patients.","Max tolerated dose not yet reached for ALG.APV-527; dosing continues in cohort five."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093356","json":"https://secwatch.observer/filing/0000950170-24-093356.json","markdown":"https://secwatch.observer/filing/0000950170-24-093356.md","text":"https://secwatch.observer/filing/0000950170-24-093356.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024093356/0000950170-24-093356-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024093356/apvo-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:01:32.559702+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}